Form 4: Madrigal Pharmaceuticals Director Kenneth Bate Reports Stock Sales and Option Exercises

Director Kenneth Bate reports exercising stock options and selling shares of Madrigal Pharmaceuticals on February 27, 2025.

Summary

• Kenneth Bate, a director of Madrigal Pharmaceuticals, reported transactions involving the company's stock on February 27, 2025.
• Bate exercised stock options to acquire a total of 20,000 shares at prices of $111.06, $65.06, and $9.45.
• Concurrently, Bate sold 17,790 shares of common stock at prices ranging from $351.0073 to $360.0662.
• Following these transactions, Bate directly owns 1,912 shares of Madrigal Pharmaceuticals common stock.
• Bate also holds options to purchase 5,470 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard reporting of stock transactions by a company director. The transactions themselves don't necessarily indicate a positive or negative outlook.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may interpret the director's stock sales as a signal, although it's common for executives to diversify their holdings.

Key Dates

Keywords

Form 4, Madrigal Pharmaceuticals, MDGL, Director, Kenneth Bate, Stock Options, Stock Sale, Beneficial Ownership